Bone mineral density in women who received ethinylestradiol 20 µg/drospirenone 3 mg administered as a fixed extended or conventional 28-day regimen in the comparative and safety extension phases (full analysis set)
| Fixed extended | Conventional 28-day | Treatment difference (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| BMD (g/cm2) | Baseline (n=38) | Week 51 (comparative) (n=23) | Week 51 (safety) (n=6) | Baseline (n=42) | Week 51 (comparative) (n=37) | Week 51 (safety) (n=16) | Baseline | Week 51 (comparative) | Week 51 (safety) |
| Lumbar spine | 1.08 (0.08) | 1.09 (0.08) | 1.07 (0.07) | 1.09 (0.08) | 1.09 (0.09) | 1.08 (0.08) | −0.02 (−0.04–0.01) | 0 (−0.03–0.03) | −0.01 (−0.06–0.03) |
| Femoral neck (left hip) | 0.90 (0.09) | 0.91 (0.08) | 0.96 (0.06) | 0.90 (0.10) | 0.90 (0.10) | 0.91 (0.11) | −0.01 (−0.03–0.01) | 0.01 (−0.02–0.04) | 0.04 (−0.01–0.10) |
| Total hip (left hip) | 1.00 (0.08) | 1.02 (0.08) | 1.03 (0.07) | 1.02 (0.09) | 1.03 (0.09) | 1.03 (0.08) | −0.02 (−0.04–0.03) | −0.01 (−0.03–0.02) | 0.01 (−0.03–0.05) |
| Data shown as mean (SD) unless otherwise stated. Data represent the average of two corrected measurements. BMD, bone mineral density; CI, confidence interval. | |||||||||